Cetuximab as Therapy for Recurrent Non-Small Cell Lung Cancer Patients Who Have Received Prior Therapy
August 2, 2012 updated by: Lecia V. Sequist
A Phase II Trial of Cetuximab (c225) as Therapy for Recurrent Non-Small Cell Lung Cancer in Patients Who Have Received Prior Therapy With Tyrosine Kinase Inhibitor Directed Against the EGFR Pathway
The purpose of this research study is to find out how well cetuximab works in treating NSCLC in patients who have been previously treated with a class of drug called tyrosine kinase inhibitor (TKI).
Cetuximab is a protein that is designed to block a substance in cancer cells called "epidermal growth factor receptor" or EGFR.
EGFR helps cancer cells grow.
Study Overview
Detailed Description
- Participants on this study will receive cetuximab by infusion intravenously once per week and may continue to receive weekly cetuximab infusions until their disease progresses or they experience unacceptable side effects.
- The following will be performed every 4 weeks while they are receiving study treatments: Physical examination; performance status; and blood work. A CT scan of the chest and upper abdomen will be performed every 8 weeks.
Study Type
Interventional
Enrollment (Actual)
56
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Dana-Farber Cancer Institute
-
Boston, Massachusetts, United States, 02114
- Massachusetts General Hospital
-
Boston, Massachusetts, United States, 02115
- Beth Israel Deaconess Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Pathologically confirmed stage IIIB or IV recurrent or progressive NSCLC
- Patients must have progressed while receiving treatment with a tyrosine kinase inhibitor targeting the EGFR pathway
- Measurable disease, as defined by RECIST criteria
- Patients must have a suitable frozen or paraffin-embedded tissue sample available for EGFR mutational analysis. Prior EGFR mutational analyses are allowable
- Patients with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 3 weeks prior to enrollment and be clinically stable
- ECOG Performance Status 0-2
- 18 years of age or older
- Negative pregnancy test within 7 days of treatment or be categorized as not of child-bearing potential
- Bone marrow function, renal function, hepatic function as outlined in protocol
Exclusion Criteria:
- Women who are pregnant of breastfeeding
- Active concurrent malignancy
- Major thoracic or abdominal surgery within 30 days prior to the first infusion of cetuximab
- Significant history of uncontrolled cardiac disease
- Uncontrolled seizure disorder, or active neurological disease
- Prior severe infusion reactions to a monoclonal antibody
- Prior chemotherapy regimen within 21 days prior to study entry
- Any EGFR tyrosine kinase inhibitor within 14 days of study entry
- Radiation therapy within 14 days prior to the first infusion of cetuximab
- Acute hepatitis or known HIV
- Active or uncontrolled infection
- Any concurrent chemotherapy or any other investigational agent(s)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Cetuximab
400mg/m2 IV x 1 and then 250mg/m2 IV weekly
|
Given intravenously once per week.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Response Rate by CT Scan Using RECIST Criteria
Time Frame: 8 weeks
|
8 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Progression-free Survival
Time Frame: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2006
Primary Completion (Actual)
September 1, 2009
Study Completion (Actual)
September 1, 2009
Study Registration Dates
First Submitted
December 28, 2007
First Submitted That Met QC Criteria
June 6, 2008
First Posted (Estimate)
June 10, 2008
Study Record Updates
Last Update Posted (Estimate)
September 6, 2012
Last Update Submitted That Met QC Criteria
August 2, 2012
Last Verified
August 1, 2012
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-026
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.